The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Novartis Pharmaceuticals Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (10)
- 2024 (20)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Sponsor content
547 result(s) found, displaying 21 to 30
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PLUVICTO lutetium (177Lu) vipivotide tetraxetan 1000 MBq/mL solution for injection vial.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Designation or determinationPriority review
-
Prescription medicine registrationActive ingredients: eltrombopag olamine.
-
Sep-2024Prescription medicine evaluationActive ingredient: lutetium (177Lu) oxodotreotide.
-
Prescription medicine registrationActive ingredients: iptacopan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVLOIRE carbamazepine 100 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AVLOIRE carbamazepine 200 mg tablet blister pack.
-
Prescription medicine registrationActive ingredients: lutetium (177Lu) vipivotide tetraxetan.